Stay away from coadministration with sensitive CYP3A substrates. If coadministration unavoidable, keep an eye on for adverse reactions and cut down CYP3A substrate dose in accordance with solution labeling. Keep away from concomitant usage of tucatinib with CYP3A substrates, exactly where nominal